Head-To-Head Survey: GSK (NYSE:GSK) & United-Guardian (NASDAQ:UG)

GSK (NYSE:GSK) and United-Guardian (NASDAQ:UG) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Risk & Volatility

GSK has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, United-Guardian has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Institutional & Insider Ownership

15.7% of GSK shares are held by institutional investors. Comparatively, 23.2% of United-Guardian shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 29.0% of United-Guardian shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares GSK and United-Guardian’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
United-Guardian	22.01%	22.24%	19.12%

Dividends

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.8%. United-Guardian pays an annual dividend of $0.60 per share and has a dividend yield of 8.7%. GSK pays out 55.3% of its earnings in the form of a dividend. United-Guardian pays out 111.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. United-Guardian has raised its dividend for 1 consecutive years. United-Guardian is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for GSK and United-Guardian, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3	12	4	0	2.05
United-Guardian	0	1	0	0	2.00

GSK presently has a consensus target price of $55.33, indicating a potential upside of 18.20%. Given GSK’s stronger consensus rating and higher probable upside, analysts plainly believe GSK is more favorable than United-Guardian.

Valuation and Earnings

This table compares GSK and United-Guardian”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07 billion	2.20	$7.54 billion	$3.20	14.63
United-Guardian	$10.55 million	3.00	$2.11 million	$0.54	12.78

GSK has higher revenue and earnings than United-Guardian. United-Guardian is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Summary

GSK beats United-Guardian on 9 of the 17 factors compared between the two stocks.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

About United-Guardian

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.